Novel Treatment Paradigms: Primary IgA Nephropathy by Haresh Selvaskandan, Jonathan Barratt, Chee Kay Cheung

Get full text

WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN by Jonathan Barratt, Robert Brenner, Kerry Cooper, Xuelian Wei, Richard Lafayette

Get full text

Decile-based index drought insurance to help improve income stability for wheat producers in Australia by Jonathan Barratt, Jarrod Kath, Brian Collins, Shahbaz Mushtaq, Duc-Anh An-Vo

Get full text

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL by Jonathan Barratt, Brad Rovin, Edward Murphy, Radko Komers, Hernán Trimarchi, Vlado Perkovic

Get full text

The importance of patient engagement when promoting age-inclusive research by Lydia E. Roberts, James O. Burton, Manish D. Sinha, Jonathan Barratt, Louise Oni

Get full text

WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY by Jonathan Barratt, Jürgen Flöge, Vishal Duggal, Nadine Schmit, Ji Cheng, Jeannette Lo, Brad Rovin

Get full text

WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY by Jonathan Barratt, Miguel Ángel Pérez Valdivia, Dario Roccatello, Katherine Garlo, Kara Rice, Richard Lafayette

Get full text

The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A Nephropathy by Ayako Koizumi, Yoshihito Nihei, Kazuaki Mori, Ryousuke Aoki, Hitoshi Suzuki, Jonathan Barratt, Yusuke Suzuki

Get full text

WCN25-3817 LOIN PAIN IN RARE KIDNEY DISEASE: ANALYSIS OF 3867 QUESTIONNAIRE RESPONSES WITH LINKED DATA FROM THE UK NATIONAL REGISTRY OF RARE KIDNEY DISEASES (RaDaR) by Katie Wong, Kristina Newman, Haresh Selvaskandan, Jonathan Barratt, Zoe Plummer, Susan Pywell, Sherry Masoud, Daniel P. Gale

Get full text

WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIVE TITERS TO DIPHTHERIA AND TETANUS AND BALANCED INFECTIONS VS PLACEBO WITH A FOCUS ON COVID-19 by Jonathan Barratt, Bart Maes, Rubeen Israni, Xuelian Wei, Vladimir Tesar, Gerald Appel, Yusuke Suzuki, Celia Lin, Richard Lafayette

Get full text

WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY by Hernán Trimarchi, Jonathan Barratt, Jai Radhakrishnan, Dana V. Rizk, Bess Sorensen, Jocelyn Leiske, Zeeshan Khawaja, Kirk Campbell, Vlado Perkovic

Get full text

Long-Term Therapeutic Plasma Exchange to Prevent End-Stage Kidney Disease in Adult Severe Resistant Henoch-Schonlein Purpura Nephritis by Patrick Hamilton, Olumide Ogundare, Ammar Raza, Arvind Ponnusamy, Julie Gorton, Hana Alachkar, Jamil Choudhury, Jonathan Barratt, Philip A. Kalra

Get full text

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN) by Jonathan Barratt, Biruh Workeneh, Sung Gyun Kim, Eun Young Lee, Chun Lam, Bess Sorensen, Yuanbo Song, Zeeshan Khawaja, Laura Kooienga

Get full text

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL by Chee Kay Cheung, Stephanie Moody, Neeraj Dhaun, Siân Griffin, Alexandra Howson, Alex Mercer, Matthew Sayer, Smeeta Sinha, Lisa Willcocks, Jonathan Barratt

Get full text

WCN25-3803 Design of Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-Center, Multi-Arm and Multi-Stage by Suceena Alexander, Selvin Sundar Raj Raj, Santosh Varughese, Vinoi George David, Nisha Jose, Reka K, Babak Choodari-Oskooei, Jonathan Barratt, George T. John

Get full text

WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL by Chee Kay Cheung, Stephanie Moody, Neeraj Dhaun, Siân Griffin, Alexandra Howson, Radko Komers, Alex Mercer, Matthew Sayer, Smeeta Sinha, Lisa Willcocks, Jonathan Barratt

Get full text

WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY by Jonathan Barratt, Bart Maes, Celia Lin, Xuelian Wei, Sean Barbour, Richard Phoon, Sung Gyun Kim, Vladimir Tesar, Jürgen Floege, Vivekanand Jha, Richard Lafayette

Get full text

WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL by Jonathan Barratt, Richard Lafayette, Hitoshi Suzuki, Sreelatha Melamadothil, Laura Kooeinga, Chula Herath, Muh Geot Wong, David Oldach, Asher Schachter, Mohit Mathur, Yusuke Suzuki

Get full text

WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY by Uptal Patel, Jürgen Flöge, Jonathan Barratt, Richard Lafayette, Brian Schwartz, Paul Manser, Lisa Kivman, Stefan Ha¨rtle, Nicola Faulhaber, Anjali Thakur, Sean Barbour

Get full text

WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN) by Lisa Kivman, Tabea Kraft, Julia Rauser, Rainer Boxhammer, Stefan Hartle, Brian Schwartz, Paul Manser, Leslie Chinn, Uptal Patel, Donna Flesher, Krzysztof Kiryluk, Jonathan Barratt

Get full text